First-In-Class Dapaglifozin Headed For FDA Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
In highly safety-conscious climate for diabetes drugs, safety of SGLT-2 inhibitor dapagliflozin is bound to face intense scrutiny.